Further assessment is needed to understand if these treatment recommendations were eventually adopted and if adoption leads to better outcomes,” researchers wrote.

The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.

Transdermal estradiol patches may be an alternative to LHRHas when combined with ARPIs to treat mHSPC, researchers say.

Tremtelectogene empogeditemcel (trem-cel) may make gemtuzumab ozogamicin maintenance safer for patients with high-risk acute myeloid leukemia (AML), according to results of a phase 1/2 trial presented ...

NSAID use is associated with an increased risk of death from RCC among women but not among men, researchers found.

The FDA has approved the biologics license applications for Ospomyv and Xbryk, biosimilars to Prolia and Xgeva, respectively.

Although there was a significant decline in the age-adjusted incidence-based mortality rate from 2006 to 2020, our study did not show a significant improvement in survival outcomes,” the researchers ...

(HealthDay News) — Overdiagnosis of thyroid cancer remains a persistent problem in the United States, researchers reported in The Lancet Diabetes & Endocrinology.

Consuming a lower-fat diet and taking a fish oil supplement daily reduced the Ki-67 index in patients with prostate cancer on active surveillance.